Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zelicapavir - Enanta Pharmaceuticals

Next Previous
X
Search
Drug Profile

Zelicapavir - Enanta Pharmaceuticals

Alternative Names: EDP-938; EP 023938

Latest Information Update: 12 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 05 Aug 2024 Enanta Pharmaceuticals completes enrolment in its phase II RSVPEDs trial for Respiratory syncytial virus infections (In infants) in ISA, United Kingdom, Taiwan, Spain, South Africa, Romania, New Zealand, Poland, Mexico, South Korea, Israel, Germany, Brazil, Australia, Argentina (NCT04816721)
  • 30 Sep 2023 Enanta Pharmaceuticals terminates phase-II trial in Respiratory syncytial virus infections (In adolescents, In adults) in United Kingdom, Turkey, Spain, South Africa, Taiwan, Poland, Mexico, South Korea, Italy, Israel, Greece, Germany, France, China, Canada, Belgium, Australia, Argentina, Colombia (PO) before September 2023(NCT04633187) (EudraCT2020-002213-18)
  • 09 Oct 2022 Phase-II clinical trials in Respiratory syncytial virus infections (In infants) in United Kingdom, Taiwan, Spain, South Africa, Romania, New Zealand, Poland, Mexico, South Korea, Israel, Germany, Brazil, Australia, Argentina (PO), prior to October 2022 (NCT04816721)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top